Tempero Pharmaceuticals

Tempero Pharmaceuticals was a private immunology-focused biotechnology company based in Cambridge, Massachusetts that worked on next-generation small-molecule therapies for autoimmune and inflammatory diseases. The company's scientific approach centered on selectively suppressing T helper 17 (Th17) biology while enhancing specialized regulatory T cell activity. Its best-known disclosed program was TMP778, a small-molecule ROR\u03b3t inverse agonist investigated for psoriasis and related immune-mediated disorders. Publicly available sources indicate the company was formed in 2009, operated as a GSK-backed or GSK-affiliated entity, and is now closed. Available evidence suggests its pipeline did not progress to late-stage clinical development and the lead disclosed asset was ultimately discontinued.